Darbitop (Darbepoetin Alfa) is an erythropoiesis-stimulating agent produced in Chinese hamster ovary (CHO) cells by recombinant DNA technology. The final processed form is a 165-amino acid protein containing 5 N-linked oligosaccharide chains and 1 O-linked oligosaccharide chain. Darbepoetin Alfa injection causes the bone marrow to produce red blood cells in patients with severe anemia. Darbepoetin may be used for patients on kidney dialysis or for those not on dialysis.
Darbepoetin Alfa 25mcg/ 0.42ml, 40mcg/0.4ml, 60mcg/0.3ml
MODE OF ACTION:
Darbepoetin Alfa stimulates erythropoiesis by the same mechanism as endogenous erythropoietin. Darbepoetin Alfa binds to the erythropoietin receptor on erythroid progenitor cells, stimulating RBC production and differentiation Binding of erythropoietin to the erythropoietin receptor leads to receptor dimerization, which facilitates activation of JAK-STAT signaling pathways within the cytosol. Activated STAT (signal transducers and activators of transcription) proteins are then translocated to the nucleus where they serve as transcription factors which regulate the activation of specific genes involved in cell division or differentiation.
- CKD patients on Dialysis
- CKD patients not on Dialysis
- Cancer patients on Chemotherapy
Recommended starting dose for patients with CKD not on dialysis: 0.45 mcg/kg intravenously or subcutaneously at 4 week intervals.
This information is for registered medical practitioner only. Anyone other than medical practitioner should consult medical practitioner before using this product.